Methazolamide structure
|
Common Name | Methazolamide | ||
|---|---|---|---|---|
| CAS Number | 554-57-4 | Molecular Weight | 236.272 | |
| Density | 1.8±0.1 g/cm3 | Boiling Point | 402.0±28.0 °C at 760 mmHg | |
| Molecular Formula | C5H8N4O3S2 | Melting Point | 208ºC (dec.) | |
| MSDS | Chinese USA | Flash Point | 196.9±24.0 °C | |
| Symbol |
GHS07, GHS08 |
Signal Word | Warning | |
Use of MethazolamideMethazolamide is a carbonic anhydrase inhibitor used to treat glaucoma.Target: Carbonic AnhydraseMethazolamide is a carbonic anhydrase inhibitor with Ki of 50 nM, 14 nM and 36 nM for hCA I, hCA II and bCA IV isoforms, respectively [1]. Methazolamide is of strength equal to acetazolamide, another carbonic anhydrase inhibitor used to treat irregular breathing disorders. However, methazolamide differs from acetazolamide in that it fails to activate Ca2+-dependent potassium channels in skeletal muscles. Methazolamide does not impair respiratory work performance in anesthetized rabbits [2]. Oral administration of methazolamide decreases IOPs and AHFRs in clinically normal dogs, with effectiveness diminishing in the evening [3]. |
| Name | Methazolamide |
|---|---|
| Synonym | More Synonyms |
| Description | Methazolamide is a carbonic anhydrase inhibitor used to treat glaucoma.Target: Carbonic AnhydraseMethazolamide is a carbonic anhydrase inhibitor with Ki of 50 nM, 14 nM and 36 nM for hCA I, hCA II and bCA IV isoforms, respectively [1]. Methazolamide is of strength equal to acetazolamide, another carbonic anhydrase inhibitor used to treat irregular breathing disorders. However, methazolamide differs from acetazolamide in that it fails to activate Ca2+-dependent potassium channels in skeletal muscles. Methazolamide does not impair respiratory work performance in anesthetized rabbits [2]. Oral administration of methazolamide decreases IOPs and AHFRs in clinically normal dogs, with effectiveness diminishing in the evening [3]. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.8±0.1 g/cm3 |
|---|---|
| Boiling Point | 402.0±28.0 °C at 760 mmHg |
| Melting Point | 208ºC (dec.) |
| Molecular Formula | C5H8N4O3S2 |
| Molecular Weight | 236.272 |
| Flash Point | 196.9±24.0 °C |
| Exact Mass | 236.003784 |
| PSA | 144.03000 |
| LogP | 0.13 |
| Vapour Pressure | 0.0±0.9 mmHg at 25°C |
| Index of Refraction | 1.737 |
| Storage condition | 2-8°C |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
| Symbol |
GHS07, GHS08 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H302 + H312 + H332-H351 |
| Precautionary Statements | P261-P280-P301 + P312 + P330 |
| Hazard Codes | Xn:Harmful |
| Risk Phrases | R20/21/22;R40 |
| Safety Phrases | S22-S36 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | 3 |
| RTECS | AC6350000 |
| HS Code | 2935009090 |
| Precursor 1 | |
|---|---|
| DownStream 0 | |
| HS Code | 2935009090 |
|---|---|
| Summary | 2935009090 other sulphonamides VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:35.0% |
|
Inhibition of hyperactivity and impulsivity by carbonic anhydrase inhibitors in spontaneously hypertensive rats, an animal model of ADHD.
Psychopharmacology 232 , 3763-72, (2015) Dysregulation of noradrenergic and dopaminergic systems is involved in the pathology of attention deficit hyperactivity disorder (ADHD). Carbonic anhydrase (CA) has been reported to affect monoamine t... |
| N-[(2E)-5-(aminosulfonyl)-3-methyl-1,3,4-thiadiazol-2(3H)-ylidene]acetamide |
| methazolamide |
| Methazolamide [BAN:INN:JAN] |
| Acetamide, N-[(2E)-5-(aminosulfonyl)-3-methyl-1,3,4-thiadiazol-2(3H)-ylidene]- |
| Methazolamide (JAN/USP) |
| EINECS 209-066-7 |
| N-(4-Methyl-2-sulfamoyl-D2-1,3,4-thiadiazolin-5-ylidene)acetamide |
| Metazolamide [DCIT] |
| Acetamide, N-[(2Z)-5-(aminosulfonyl)-3-methyl-1,3,4-thiadiazol-2(3H)-ylidene]- |
| 5-Acetylamino-4-methyl-D2-1,3,4-thiadiazoline-2-sulfonamide |
| NEPTAZANE |
| N1-[5-(aminosulfonyl)-3-methyl-2,3-dihydro-1,3,4-thiadiazol-2-yliden]acetamide |
| 4-27-00-08221 (Beilstein Handbook Reference) |
| N-[(2Z)-3-Methyl-5-sulfamoyl-1,3,4-thiadiazol-2(3H)-ylidene]acetamide |
| N-[5-(Aminosulfonyl)-3-methyl-1,3,4-triadiazol-2(3H)-ylidene]acetamide |
| N-[(2E)-3-Methyl-5-sulfamoyl-1,3,4-thiadiazol-2(3H)-ylidene]acetamide |
| MFCD00083416 |
| N-(3-methyl-5-sulfamoyl-1,3,4-thiadiazol-2-ylidene)acetamide |